This meta-analysis of randomized controlled trials (RCTs) examined the efficacy and safety of minocycline for three major mental disorders: schizophrenia, bipolar disorder and major depressive disorder (MDD).
Methods:
A systematic literature search of major electronic databases was conducted. Meta-analysis of clinical efficacy as defined by the respective studies, all-cause discontinuation, adverse drug reactions (ADRs) with standardized mean difference (SMD) and risk ratios (RRs) and their 95% confidence intervals (CI) was conducted using random-effects model. Quality assessment was performed with the Jadad scale and Cochrane risk of bias.
Results:
Sixteen RCTs (n=1357) on minocycline (50–300 mg/day) for schizophrenia (13 RCTs, n=1196), bipolar depression (1 RCT, n=49), and MDD (2 RCTs, n=112) were analyzed separately by diagnosis. Twelve RCTs mentioned randomized allocation specifically; the weighted Jadad scores were 4.0. Adjunctive minocycline outperformed placebo in improving total psychopathology [SMD: −0.45 (95%CI: −0.73, −0.16), p=0.002; I2=77%], positive [SMD: −0.15 (95%CI: −0.28, −0.02), p=0.02; I2=0%], negative [SMD: −0.62 (95%CI: −0.95, −0.28), p=0.0003; I2=85%] and general psychopathology scores [SMD: −0.28 (95%CI: −0.53, −0.03), p=0.03; I2=59%] in schizophrenia. Minocycline showed no significant effect on depressive and manic symptoms in both bipolar depression and MDD. Minocycline caused significantly less headache (p=0.02, number-needed-to-harm=14, 95%CI=5–14) than placebo in schizophrenia. All-cause discontinuation and other ADRs were similar between minocycline and placebo in each diagnostic category.
Conclusion:
In this meta-analysis, adjunctive minocycline appeared to be efficacious and safe for schizophrenia. However, the efficacy of adjunctive minocycline for bipolar depression or MDD could not be demonstrated.
AndreasenNC (1983) Scale for the Assessment of Negative Symptoms (SANS). IA: University of Iowa: Iowa City.
2.
AndreasenNC (1984) Scale for the Assessment of Positive Symptoms (SAPS). IA: University of Iowa: Iowa City.
3.
AngelucciFMathãAAAloeL (2004) Neurotrophic factors and CNS disorders: Findings in rodent models of depression and schizophrenia. Prog Brain Res146: 151–165.
4.
AtkinsDBestDBrissPA, et al. (2004) Grading quality of evidence and strength of recommendations. BMJ328: 1490.
5.
BalshemHHelfandMSchunemannHJ, et al. (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol64: 401–406.
6.
BerkMKapczinskiFAndreazzaAC, et al. (2011) Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev35: 804–817.
7.
BerkMWilliamsLJJackaFN, et al. (2013) So depression is an inflammatory disease, but where does the inflammation come from?BMC Med11: 200.
8.
BrauerRHerrero-ZazoMBarlowDJ, et al. (2019) Minocycline and the risk of acute psychiatric events in adolescence: A self-controlled case series. J Psychopharmacol33: 466–471.
9.
CharlsonFJFerrariAJSantomauroDF, et al. (2018) Global epidemiology and burden of schizophrenia: Findings from the Global Burden of Disease Study 2016. Schizophr Bull44: 1195–1203.
10.
ChaudhryIBHallakJHusainN, et al. (2012) Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol26: 1185–1193.
11.
ChavesCMarqueCRTrzesniakC, et al. (2009) Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: An update. Braz J Med Biol Res42: 1002–1014.
12.
DeakinBSucklingJBarnesTRE, et al. (2018) The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): A randomised, double-blind, placebo-controlled trial. Lancet Psychiatry5: 885–894.
13.
DeanOMDatafrancoJGiorlandoF, et al. (2012) Minocycline: Therapeutic potential in psychiatry. CNS Drugs26: 391.
14.
DeanOMKanchanatawanBAshtonM, et al. (2017) Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial. Aust N Z J Psychiatry51: 829–840.
15.
DerSimonianRLairdN (1986) Meta-analysis in clinical trials. Control Clin Trials7: 177–188.
16.
DuvalSTweedieR (2000) Trim and fill: A simple funnel-plot–based method of testing and adjusting for publication bias in meta-analysis. Biometrics56: 455–463.
17.
EcheverriaKOLascolaKMGiguereS, et al. (2017) Pulmonary disposition and pharmacokinetics of minocycline in adult horses. Am J Vet Res78: 1319–1328.
18.
EggerMDavey SmithGSchneiderM, et al. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ315: 629–634.
19.
Emadi-KouchakHMohammadinejadPAsadollahi-AminA, et al. (2016) Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: A double-blind, placebo-controlled, randomized trial. Int Clin Psychopharmacol31: 20–26.
20.
EmilianiFESedlakTWSawaA (2014) Oxidative stress and schizophrenia. Curr Opin Psychiatry27: 185–190.
21.
FeigensonKAKusnecovAWSilversteinSM (2014) Inflammation and the two-hit hypothesis of schizophrenia. Neurosci Biobehav Rev38: 72–93.
22.
FerrariAJSomervilleAJBaxterAJ, et al. (2013) Global variation in the prevalence and incidence of major depressive disorder: A systematic review of the epidemiological literature. Psychol Med43: 471–481.
23.
FerrariAJStockingsEKhooJP, et al. (2016) The prevalence and burden of bipolar disorder: Findings from the Global Burden of Disease Study 2013. Bipolar Disord18: 440–450.
24.
FondGHamdaniNKapczinskiF, et al. (2014) Effectiveness and tolerance of anti-inflammatory drugs’ add-on therapy in major mental disorders: A systematic qualitative review. Acta Psychiatrica Scandinavica129: 163–179.
25.
FriesGRVasconcelosmorenoMPGubertC, et al. (2014) Early apoptosis in peripheral blood mononuclear cells from patients with bipolar disorder. J Affect Disord152–154: 474–477.
26.
GengQZhangQEWangF, et al. (2018) Comparison of comorbid depression between irritable bowel syndrome and inflammatory bowel disease: A meta-analysis of comparative studies. J Affect Disord237: 37–46.
27.
GhanizadehADehbozorgiSOmraniSigaroodiM, et al. (2014) Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial. Recent Pat Inflamm Allergy Drug Discov8: 211–215.
28.
GoldsmithDRRapaportMHMillerBJ (2016) A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry21: 1696–1709.
29.
HamdaniNDoukhanRKurtlucanO, et al. (2013) Immunity, inflammation, and bipolar disorder: Diagnostic and therapeutic implications. Curr Psychiatry Rep15: 387.
30.
HashimotoKIshimaT (2010) A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: Translation initiation [corrected] factor eIF4AI. PLoS One5: e15430.
31.
Herrero-ZazoMBrauerRGaughranF, et al. (2018) Examining the potential preventative effects of minocycline prescribed for acne on the incidence of severe mental illnesses: A historical cohort study. J Psychopharmacol32: 559–568.
32.
HigginsJHigginsJ (2008) Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons.
33.
HigginsJPThompsonSG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med21: 1539–1558.
34.
HolmesSEHinzRConenS, et al. (2017) Elevated translocator protein in anterior cingulate in major depression and a role for inflammation in suicidal thinking: A positron emission tomography study. Biol Psychiatry83.
35.
HomsiSPiaggioTCrociN, et al. (2010) Blockade of acute microglial activation by minocycline promotes neuroprotection and reduces locomotor hyperactivity after closed head injury in mice: A twelve-week follow-up study. J Neurotrauma27: 911–921.
36.
HopeSHosethEDiesetI, et al. (2015) Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls. Schizophr Res165: 188–194.
37.
HuJShengSMHuCC, et al. (2017) The effect of minocycline combined with risperidone on negative symptoms and cognitive function in patients with early schizophrenia [In Chinese]. J Int Psychiatry44: 417–419.
38.
HusainMIChaudhryIBHusainN, et al. (2017) Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial. J Psychopharmacol31: 1166–1175.
39.
JadadARMooreRACarrollD, et al. (1996) Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Control Clin Trials17: 1–12.
40.
KaleliogluTAkkusMKaramustafaliogluN, et al. (2015) Neutrophil-lymphocyte and platelet-lymphocyte ratios as inflammation markers for bipolar disorder. Psychiatry Res228: 925–927.
41.
KaySRFiszbeinAOplerLA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull13: 261–276.
42.
KellyDLSullivanKMMcEvoyJP, et al. (2015) Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol35: 374–381.
43.
KellyDLVyasGRichardsonCM, et al. (2011) Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr Res133: 257–258.
44.
KhandakerGMCousinsLDeakinJ, et al. (2015) Inflammation and immunity in schizophrenia: Implications for pathophysiology and treatment. Lancet Psychiatry2: 258–270.
45.
Khodaie-ArdakaniM-RMirshafieeOFarokhniaM, et al. (2014) Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. Psychiatry Res215: 540–546.
46.
Kiecolt-GlaserJKDerryHMFagundesCP (2015) Inflammation: Depression fans the flames and feasts on the heat. Am J Psychiatry172: 1075–1091.
47.
KimSSKongPJKimBS, et al. (2004a) Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch Pharm Res27: 314–318.
48.
KimSSKongPJKimBS, et al. (2004b) Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch Pharm Res27: 314–318.
49.
Kohler-ForsbergOCNLHjorthojC, et al. (2019) Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: Meta-analysis of clinical trials. Acta Psychiatr Scand139: 404–419.
50.
KroghJBenrosMEJørgensenMB, et al. (2014) The association between depressive symptoms, cognitive function, and inflammation in major depression. Brain Behav Immun35: 70–76.
51.
LeboyerMSorecaIScottJ, et al. (2012) Can bipolar disorder be viewed as a multi-system inflammatory disease?J Affect Disord141: 1–10.
52.
LeuchtSKomossaKRummel-KlugeC, et al. (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry166: 152–163.
53.
LeuchtSRothePDavisJM, et al. (2013) Equipercentile linking of the BPRS and the PANSS. Eur Neuropsychopharmacol23: 956–959.
54.
Levkovitch-VerbinHWaserzoogYVanderS, et al. (2014) Minocycline upregulates pro-survival genes and downregulates pro-apoptotic genes in experimental glaucoma. Graefes Arch Clin Exp Ophthalmol252: 761–772.
55.
LevkovitzYMendlovichSRiwkesS, et al. (2010) A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry71: 138–149.
56.
LinSWeiXXuY, et al. (2003) Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons. Life Sci72: 1635–1641.
57.
LindeKClausiusNRamirezG, et al. (1997) Are the clinical effects of homeopathy placebo effects? A meta-analysis of placebo-controlled trials. Lancet350: 834–843.
58.
LiuFGuoXWuR, et al. (2014) Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial. Schizophr Res153: 169–176.
59.
LiuZFanYWonSJ, et al. (2007) Chronic treatment with minocycline preserves adult new neurons and reduces functional impairment after focal cerebral ischemia. Stroke38: 146–152.
60.
MardiniHEKipKEWilsonJW (2004) Crohn’s disease: A two-year prospective study of the association between psychological distress and disease activity. Dig Dis Sci49: 492–497.
61.
MathersCFatDMBoermaJT (2008) The global burden of disease: 2004 update. Geneva: World Health Organization.
62.
MiyaokaTWakeRFuruyaM, et al. (2012) Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study. Prog Neuropsychopharmacol Biol Psychiatry37: 222–226.
63.
MiyaokaTYasukawaRYasudaH, et al. (2008) Minocycline as adjunctive therapy for schizophrenia: An open-label study. Clin Neuropharmacol31: 287–292.
64.
MoherDLiberatiATetzlaffJ, et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med151: 264–269, W264.
65.
MurroughJWHurykKMMaoX, et al. (2018) A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. J Affect Disord230: 56–64.
66.
NajjarSPearlmanDM (2015) Neuroinflammation and white matter pathology in schizophrenia: Systematic review. Schizophr Res161: 102–112.
67.
NunesSOVargasHOPradoE, et al. (2013) The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence. Neurosci Biobehav Rev37: 1336–1345.
68.
OverallJEGorhamDR (1962) The brief psychiatric rating-scale. Psychol Rep10: 799–812.
69.
OyaKKishiTIwataN (2014) Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: A systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol29: 483–491.
70.
PabrejaKDuaKSharmaS, et al. (2011) Minocycline attenuates the development of diabetic neuropathic pain: Possible anti-inflammatory and anti-oxidant mechanisms. Eur J Pharmacol661: 15–21.
71.
QurashiICollinsJDChaudhryIB, et al. (2014) Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia. J Psychopharmacol28: 707–708.
72.
ReusGZAbelairaHMMacielAL, et al. (2015) Minocycline protects against oxidative damage and alters energy metabolism parameters in the brain of rats subjected to chronic mild stress. Metab Brain Dis30: 545–553.
73.
RickardsH (2005) Depression in neurological disorders: Parkinson’s disease, multiple sclerosis, and stroke. J Neurol Neurosurg Psychiatry76(Suppl 1): i48–52.
74.
RosenblatJDMcIntyreRS (2018) Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials. J Affect Disord227: 219–225.
75.
RosenthalR (1979) The file drawer problem and tolerance for null results. Psychol Bull86: 638–641.
76.
RushAJTrivediMHWisniewskiSR, et al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry163: 1905–1917.
77.
SavitzJBTeagueTKMisakiM, et al. (2018) Treatment of bipolar depression with minocycline and/or aspirin: An adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. Transl Psychiatry8: 27.
78.
SchildknechtSPapeRMüllerN, et al. (2011) Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. J Biol Chem286: 4991–5002.
79.
SoczynskaJKennedySHAlsuwaidanM, et al. (2014) A pilot, open-label, 8-week study evaluating the efficacy of adjunctive minocycline for the treatment of bipolar I/II depression. Int J Neuropsychopharmacol17: 133.
80.
SoczynskaJKKennedySHAlsuwaidanM, et al. (2017) A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. Bipolar Disord19: 198–213.
81.
SoczynskaJKMansurRBBrietzkeE, et al. (2012) Novel therapeutic targets in depression: Minocycline as a candidate treatment. Behav Brain Res235: 302–317.
82.
SolmiMVeroneseNThapaN, et al. (2017) Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectr22: 415–426.
83.
SongGMLiJH (2017) Effect of minocycline on negative symptoms in patients with schizophrenia and its influence on tumor necrosis factor-α [In Chinese]. Herald Med35: 529–531.
84.
SuraKBobrinB (2012) Minocycline use in a patient with multi-drug-intolerant neuropathy. J Neuropsychiatry Clin Neurosci24: 18.
85.
TangCMHwangCSChenSD, et al. (2011) Neuroprotective mechanisms of minocycline against sphingomyelinase/ceramide toxicity: Roles of Bcl-2 and thioredoxin. Free Radic Biol Med50: 710–721.
86.
TorreyEFDavisJM (2012) Adjunct treatments for schizophrenia and bipolar disorder: What to try when you are out of ideas. Clin Schizophr Relat Psychoses5: 208–216.
87.
TsaiSYChungKHHuangSH, et al. (2014) Persistent inflammation and its relationship to leptin and insulin from bipolar depression to full remission. J Appl Psychol77: 437–452.
88.
VyasGRichardsonCMSullivanKM, et al. (2013) Open-label adjunct minocycline to clozapine resolves symptoms in chronic schizophrenia. Schizophr Bull39: S357.
89.
WangYZhangHChaiF, et al. (2014) The effects of escitalopram on myocardial apoptosis and the expression of Bax and Bcl-2 during myocardial ischemia/reperfusion in a model of rats with depression. BMC Psychiatry14: 349.
90.
WeiserMLeviLBurshteinS, et al. (2018) The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial. Schizophr Res. 206: 325–332.
91.
WhitefordHADegenhardtLRehmJ, et al. (2013) Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010. Lancet382: 1575–1586.
92.
XiangYQZhengWWangSB, et al. (2017) Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol27: 8–18.
93.
ZengHH (2015) Minocycline supplementation for treatment of negative symptoms in schizophrenia and the effect on body weight: A double blind, randomized, controlled trial [In Chinese]. Schizophr Res153: 169–176.
94.
ZhangLZhengHWuR, et al. (2018) Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels. Prog Neuropsychopharmacol Biol Psychiatry85: 69–76.
95.
ZhangT (2015) Minocycline add-on to risperidone for patients with stable schizophrenia [In Chinese]. Med Inform28: 372–372.
96.
ZhengWLiXHYangXH, et al. (2018) Adjunctive memantine for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Psychol Med48: 72–81.
97.
ZhengWWangSBUngvariGS, et al. (2017) Amantadine for antipsychotic-related weight gain: Meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol37: 341–346.
98.
ZhengWXiangYTXiangYQ, et al. (2016) Efficacy and safety of adjunctive topiramate for schizophrenia: A meta-analysis of randomized controlled trials. Acta Psychiatr Scand134: 385–398.
99.
ZhuXMZhengWLiXH, et al. (2018) Adjunctive raloxifene for postmenopausal women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Schizophr Res. 197: 288–293.
100.
ZunszainPAHepgulNParianteCM (2013) Inflammation and depression. Curr Top Behav Neurosci14: 135–151.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
